Market capitalization | $990.00k |
Enterprise Value | $49.81m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.91 |
P/S ratio (TTM) P/S ratio | 0.06 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 26.09% |
Revenue (TTM) Revenue | $17.10m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Evofem Biosciences, Inc.:
1 Analyst has issued a forecast Evofem Biosciences, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 17 17 |
26%
26%
|
|
Gross Profit | 13 13 |
186%
186%
|
|
EBITDA | -9.58 -9.58 |
59%
59%
|
EBIT (Operating Income) EBIT | -10 -10 |
62%
62%
|
Net Profit | -7.94 -7.94 |
117%
117%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Saundra Pelletier |
Employees | 37 |
Founded | 2007 |
Website | www.evofem.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.